{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:17:49Z","timestamp":1778879869885,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,15]],"date-time":"2027-05-15T00:00:00Z","timestamp":1810339200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01 AA026980\\u201306"],"award-info":[{"award-number":["U01 AA026980\\u201306"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20 GM103436"],"award-info":[{"award-number":["P20 GM103436"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:33:03Z","timestamp":1774297983000},"page":"449-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Population"],"prefix":"10.1016","volume":"30","author":[{"given":"Winston","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2026.01.007_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cld.2026.01.007_bib4","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000828","article-title":"Metabolic dysfunction and alcohol-associated liver disease: a narrative review","volume":"16","author":"Dunn","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.007_bib5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cld.2026.01.007_bib8","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.14309\/ajg.0000000000002778","article-title":"Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes","volume":"119","author":"Chen","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.007_bib9","article-title":"Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score","volume":"6","author":"Sripongpun","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.01.007_bib10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049767","article-title":"Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis","volume":"12","author":"Jarvis","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.cld.2026.01.007_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"Aberg","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib13","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hep.29631","article-title":"Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population","volume":"67","author":"Aberg","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ebiom.2019.03.046","article-title":"Obesity in acute alcoholic hepatitis increases morbidity and mortality","volume":"45","author":"Parker","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cld.2026.01.007_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63453-6","article-title":"Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study","volume":"14","author":"Charatcharoenwitthaya","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2026.01.007_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s44355-024-00014-8","article-title":"Metabolic and alcohol-associated liver disease (MetALD): a representation of duality","volume":"2","author":"Leal-Lassalle","year":"2025","journal-title":"npj Gut and Liver"},{"key":"10.1016\/j.cld.2026.01.007_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.007_bib18","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","article-title":"MetALD: does it require a different therapeutic option?","volume":"80","author":"Marek","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/HEP.0000000000000381","article-title":"Emerging targets for therapy in ALD: lessons from NASH","volume":"80","author":"Singal","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.dld.2025.01.191","article-title":"Differential candidate characteristics associated with increasing ALD and MASH among liver transplant listings in the US","volume":"57","author":"Singal","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.cld.2026.01.007_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/acer.13108","article-title":"Diagnosis and treatment of alcoholic hepatitis: a systematic review","volume":"40","author":"Singal","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cld.2026.01.007_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2026.01.007_bib24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/HEP.0000000000000617","article-title":"Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease","volume":"81","author":"Norden-Krichmar","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Trepo","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.007_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biom15040469","article-title":"The role of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and other metabolic diseases","volume":"15","author":"Munte","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cld.2026.01.007_bib29","doi-asserted-by":"crossref","first-page":"01","DOI":"10.35946\/arcr.v44.1.01","article-title":"Gut-liver-brain axis and alcohol use disorder: treatment potential of fecal microbiota transplantation","volume":"44","author":"Wolstenholme","year":"2024","journal-title":"Alcohol Res"},{"key":"10.1016\/j.cld.2026.01.007_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/HEP.0000000000000344","article-title":"Gut microbiome-brain-cirrhosis axis","volume":"80","author":"Smith","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13010067","article-title":"Alcohol use disorder and the gut-brain axis: a narrative review of the role of gut microbiota and implications for treatment","volume":"13","author":"Shukla","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.cld.2026.01.007_bib32","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib33","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/s41467-022-31390-5","article-title":"Gut virome profiling identifies a widespread bacteriophage family associated with metabolic syndrome","volume":"13","author":"de Jonge","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cld.2026.01.007_bib34","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)","volume":"4","author":"RJ","year":"2024","journal-title":"Metabolism and Target Organ Damage"},{"key":"10.1016\/j.cld.2026.01.007_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4093\/dmj.2024.0042","article-title":"Metabolic dysfunction-associated steatotic liver disease and all-cause and cause-specific mortality","volume":"49","author":"Oh","year":"2025","journal-title":"Diabetes & Metabolism Journal"},{"key":"10.1016\/j.cld.2026.01.007_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/apt.18015","article-title":"Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality","volume":"60","author":"Tamaki","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.01.007_bib37","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","article-title":"Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis","volume":"22","author":"Nasr","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib38","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2026.01.007_bib39","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","article-title":"Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort","volume":"81","author":"Oh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2026.01.007_bib43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14309\/ajg.0000000000003432","article-title":"ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease","volume":"121","author":"Alkhouri","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.007_bib44","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib45","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2026.01.007_bib46","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cld.2024.06.017","article-title":"Research priorities and future landscape of clinical trials in alcohol-associated liver disease","volume":"28","author":"Kulkarni","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2026.01.007_bib47","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41575-024-00936-x","article-title":"Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement","volume":"21","author":"Lee","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib48","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/hep.30967","article-title":"Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the multiethnic cohort","volume":"71","author":"Noureddin","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib49","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1053\/j.gastro.2015.10.040","article-title":"Reply: to PMID 25865049","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.007_bib50","unstructured":"Dunn N ea. Low Fat and Low Carbohydrate Diets Are Associated with Worse Survival in Subjects with Metabolic Dysfunction and Alcohol Associated Steatotic Liver Diseases In AASLD Liver Meeting 2025."},{"key":"10.1016\/j.cld.2026.01.007_bib51","unstructured":"Dunn N ea. Low-fat or Low-carb Diets May Worsen Fibrosis in Patients with Steatotic Liver Disease, In AASLD Liver Meeting 2025."},{"key":"10.1016\/j.cld.2026.01.007_bib52","unstructured":"Dunn N ZW, Wong RJ, Younossi Z, et al. Physical activity and advanced fibrosis in MASLD, MetALD, and ALD: Insights from NHANES 2017-2020. . Under revision, Hepatology Communications."},{"key":"10.1016\/j.cld.2026.01.007_bib53","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jceh.2022.04.010","article-title":"Management of alcohol use disorder in patients with alcoholic liver disease","volume":"12","author":"Murthy","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib54","unstructured":"Resmetirom improves noninvasive markers of liver fibrosis and portal hypertension in participants with compensated MASH cirrhosis, EASL Congress, May 2025, 2025."},{"key":"10.1016\/j.cld.2026.01.007_bib55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.007_bib56","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib57","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.007_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib59","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib60","unstructured":"D. S. Novo\u2019s GLP-1 trial for alcohol-related liver disease enters Phase II."},{"key":"10.1016\/j.cld.2026.01.007_bib61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","volume":"10","author":"Krag","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib62","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib63","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2024.02.032","article-title":"Impact of longitudinal alcohol use patterns on long-term risk of cirrhosis among US veterans with steatotic liver disease","volume":"166","author":"Wong","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.007_bib64","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib65","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib66","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.007_bib67","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000686","article-title":"Treatment of alcohol use disorder in alcohol-associated liver disease: a meta-analysis","volume":"9","author":"Singal","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2026.01.007_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(21)00191-6","article-title":"Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models","volume":"7","author":"DiMartini","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(19)30451-0","article-title":"Liver transplantation in patients with alcohol-related liver disease: current status and future directions","volume":"5","author":"Mathurin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.cld.2026.01.007_bib70","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.cgh.2025.02.007","article-title":"Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments","volume":"23","author":"Israelsen","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib71","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1097\/HEP.0000000000001266","article-title":"Letter to the editor: alcohol a confounding factor in the assessment of resmetirom therapy","volume":"81","author":"Krag","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.007_bib72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","article-title":"The steatotic liver disease burden paradox: unravelling the key role of alcohol","volume":"22","author":"Torp","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000561","article-title":"Transforming steatotic liver disease management: the emerging role of GLP-1 receptor agonists","volume":"8","author":"Jensen","year":"2024","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.cld.2026.01.007_bib74","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2468-1253(25)00134-7","article-title":"GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease","volume":"10","author":"Singal","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.007_bib75","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmet.2023.02.005","article-title":"FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system","volume":"35","author":"Choi","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.cld.2026.01.007_bib76","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"Lahteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cld.2026.01.007_bib77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:50Z","timestamp":1778878670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000073"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special Population","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}